leisure time -WSS

leisure time

author：explore 2025-09-30 16:59:35 - browse：5834

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Fed up with FDA, ALS advocates consider a take

WSS

Do digital therapeutics have a future in medicine?

Commercial surrogacy can be ethical, despite pope’s claims

Chamber of Commerce, DOJ clash in court over drug prices

FDA panel to weigh safety of artificial wombs for preterm births

Grad students accuse University of California of wage theft

PBMs drew scrutiny in House hearing — and so did pharma

Wikipedia

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

knowledge

At least 13 dead in Texas as scorching temps continue

Do digital therapeutics have a future in medicine?

Hepatitis C has a cure — but many Americans still lack access to it

Some dementia cases could be undiagnosed liver disease

Hollywood unions extend contract negotiations for actors

Akili changes sales model for its ADHD video game treatment

Malaria cases in Florida and Texas: Here’s what you need to know

General Catalyst, Summa Health deal will turn on physician buy

BioMarin wins approval for gene therapy to treat hemophilia A

Congressmen charge Covid hearing ‘could have been an email’

knowledge

How the messy conversation about Dolly changed bioethics

What we need to know about Arena Bioworks

Quicker fix for pulse oximeters urged during FDA public meeting

Do digital therapeutics have a future in medicine?

Assistant physicians can help address the primary care shortage

House panel takes first step toward fixing drug shortages

hotspot

Wikipedia

hotspot

leisure time